Body Weight, Menopausal Hormone Therapy, and Risk of Breast Cancer

Treatment of the Postmenopausal Woman: Basic and Clinical Aspects, Third Edition

Volumn , Issue , 2007, Pages 569-578

  Wu, Anna H ^a   Leigh Pearce, C ^a   Spicer, Darcy V ^a   Lee, Sulggi ^a   Pike, Malalcolm C ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 85071406008     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-012369443-0/50049-1     Document Type: Chapter

References (45)

1. D Trichopoulos, B MacMahon and P Cole (1972) Menopause and breast cancer risk. J Natl Cancer Inst 48 605-613.
2. JL Kelsey and L Bernstein (1996) Epidemiology and prevention of breast cancer. Annu Rev Public Health 17 47-67.
3. GA Colditz and B Rosner (2000) Cumulative risk of breast cancer to age 70 years according to risk factor status: data from the Nurses' Health Study. Am J Epidemiol 152 950-964.
4. BE Henderson, RK Ross, HL Judd, MD Krailo and MC Pike (1985) Do regular ovulatory cycles increase breast cancer risk? Cancer 56 1206-1208.
5. B MacMahon, P Cole and J Brown (1973) Etiology of human breast cancer: a review. J Natl Cancer Inst 50 21-42.
6. D Trichopoulos, CC Hsieh, B MacMahon, et al. (1983) Age at any birth and breast cancer risk. Int J Cancer 31 701-704.
7. J Wohlfahrt and M Melbye (2001) Age at any birth is associated with breast cancer risk. Epidemiology 12 68-73.
8. MC Pike, MD Krailo, BE Henderson, JT Casagrande and DG Hoel (1983) “Hormonal”risk factors,“breast tissue age”and the age-incidence of breast cancer. Nature 303 767-770.
9. SY Cutler and JL. Young (1975) Third National Cancer Survey: incidence data vol 4 Washington DC: National Cancer Institute Monograph
10. PJ Cook, R Doll and SA Fellingham (1969) A mathematical model for the age distribution of cancer in man. Cancer 4 93-112.
11. J Cairns (2002) Somatic stem cells and the kinetics of mutagenesis and carci-nogenesis. Proc Natl Acad Sci USA 99 10567-10570.
12. B Rosner, GA Colditz and WC Willett (1994) Reproductive risk factors in a prospective study of breast cancer: The Nurses' Health Study. Am J Epidemiol 139 819-835.
13. TJ Anderson, DJ Ferguson and GM Raab (1982) Cell turnover in the“resting”human breast: influence of parity, contraceptive pill, age and literality. BrJ Cancer 46 376-382.
14. MC Pike, DV Spicer, L Dahmoush and MF Press (1993) Estrogens, progesto-gens, normal breast cell proliferation, and breast cancer risk. Epidemiol Rev 15 17-35.
15. JS Meyer and RE Connor (1982) Cell proliferation in fibrocystic disease and postmenopause breast ducts measured by thymidine labeling. Cancer 50 746-750.
16. AJ Hartz, W.A. BarboriakTN Wong A, KP Katama and AA Rim (1979) The associa-tion of obesity with infertility and related menstrual abnormalities in women. Int J Obes 3 57-73.
17. H.B.C.C.G. Endogenous Hormones Breast Cancer Collaborative Group (2003) Body mass index, serum sex hormones, and breast cancer risk in postmeno-pausal women. J Natl Cancer Inst 95 1218-1226.
18. H.B.C.C.G. Endogenous Hormones Breast Cancer Collaborative Group (2003) Free estradiol and breast cancer risk in postmenopausal women: comparison of measured and calculated values. Cancer Epidemiol Biomark Prev 12 1457-1461.
19. P van den Brandt, D Spiegelman, S-S Yaun, et al. (2000) Pooled analysis of prospective cohort studies on height, weight, and breast cancer risk. Am J Epidemiol 152 514-527.
20. R Södergard, T Backstrom, V Shanbhag and H Carstensen (1982) Calculation of free and bound fractions of testosterone and estradiol-17 beta to hu-man plasma proteins at body temperature. J Steroid Biochem 16 801-810.
21. JF Dunn, BC Nisula and D Rodbard (1981) Transport of steroid hormones: bind-ing of 21 endogenous steroids to both testosterone-binding globulin and corticosteroid-binding globulin in human plasma. JClin Endocri-nol Metab 53 58-68.
22. I Schiff, HK Sela, D Cramer, D Tulchinsky and KJ Ryan (1982) Endometrial hyperplasia in women on cyclic or continuous estrogen regimens. Fertil Steril 37 79-82.
23. MS Powers, L Schennkel, PE Darley, et al. (1985) Pharmacokinetics and pharmacodynamics of transdermal dosage forms of 17-β estradiol: comparison with conventional oral estrogens used for hormone replacemen. Am J Obstet Gynecol 152 1099-1106.
24. PL Selby and M Peacock (1986) Dose dependent response of symptoms, pitu-itary, and bone to transdermal estrogen in postmenopausal women. BMJ 293 1337-1339.
25. LE Nachtigall, U Raju, S Banerjee, L Wan and M Levitz (2000) Serum estradiol profiles in postmenopausal women undergoing three common estrogen replacement therapies: associations with sex hormone-binding globu-lin, estr. Menopause 7 243-250.
26. A Ropponen, K Aittomaki, V Vihma, MJ Tikkanen and O Ylikorkala (2005) Ef-fects of oral estradiol administration on levels of sex hormone-binding globulin in postmenopausal women with and without a history of in-trahepatic choles. J Clin Endocrinol Metab 90 3431-3434.
27. FZ Stanczyk (2002) Pharmacokinetics and potency of progestins used for hormone replacement therapy and contraception. Rev Endocrin Metab Disord 3 211-224.
28. G.H.F.B.C. Collaborative Group on Hormonal Factors in Breast Cancer (1997) Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52,705 women with breast cancer and 108,411. Lancet 350 1047-1059.
29. C Schairer, J Lubin, R Troisi, et al. (2000) Menopausal estrogen and estrogen-progestin replacement therapy and breast cancer risk. J Am Med Assoc 283 485-491.
30. W.S.C. Million Women Study Collaborators (2003) Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet 362 419-427.
31. V Beral, G Reeves and E Banks (2005) Current evidence about the effect of hormone replacement therapy on the incidence of major conditions in postmenopausal women. BrJ Obstet Gynaecol 112 692-695.
32. H.I. Women's Health Initiative (2004) Effects of conjugated equine estrogen in postmenopausal women with hysterectomy. J Am Med Assoc 291 1701-1712.
33. SA Lee, RK Ross and MC Pike (2005) An overview of menopausal oestrogen-progestin hormone therapy and breast cancer risk. Br J Cancer 92 2049-2058.
34. C Magnusson, JA Baron, N Correia, et al. (1999) Breast-cancer risk following long-term oestrogen-and oestrogen-progestin-replacement therapy. Int J Cancer 81 339-344.
35. RK Ross, A Paganini-Hill, PC Wan and MC Pike (2000) Effect of hormone replacement therapy on breast cancer risk: estrogen versus estrogen plus progestin J Natl. Cancer Inst 92 328-332.
36. PA Newcomb, L Titus-Ernstoff, KM Egan, et al. (2002) Postmenopausal es-trogen and progestin use in relation to breast cancer risk. Cancer Epi-demiol Biomarkers Prev 11 593-600.
37. JV Porch, IM Lee, NR Cook, KM Rexrode and JE Burin (2002) Estrogen-progestin replacement therapy and breast cancer risk: the Women's Health Study (United States). Cancer Causes Control 13 847-854.
38. V Kirsh and N Kreiger (2002) Estrogen and estrogen-progestin replacement therapy and risk of postmenopausal breast cancer in Canada. Cancer Causes Control 13 583-590.
39. LK Weiss, RT Burkman, KL Cushing-Haugen, et al. (2002) Hormone re-placement therapy regimens and breast cancer risk. Obstet Gynecol 100 1148-1158.
40. RT Chlebowski, SL Hendrix, RD Langer, et al. (2003) Influence of estrogen plus progestin on breast cancer and mammography in healthy post-menopausal women: the Women's Health Initiative Randomized Trial. J Am Med Assoc 289 3243-3253.
41. C Stahlberg, AT Pedersen, E Lynge, et al. (2004) Increased risk of breast cancer following different regimens of hormone replacement therapy frequently used in Europe. Int J Cancer 109 721-727.
42. H Jernstrom, PO Bendahl, J Lidfeldt, et al. (2003) A prospective study of dif-ferent types of hormone replacement therapy use and the risk of sub-sequent breast cancer: the women's health in the Lund area (WHI. Cancer Causes Control 14 673-680.
43. G Ursin, CC Tseng, A Pagini-Hill, et al. (2002) Does menopausal hormone replacement therapy interact with known factors to increase risk of breast cancer? J Clin Oncol 20 699-706.
44. D Shoupe, D Meme, G Mezrow and RA Lobo (1991) Prevention of endometrial hyperplasia in postmenopausal women with intrauterine progesterone. N Engl J Medl 325 1811-1812.
45. E Varila, T Wahlstrom and I Rauramo (2001) A 5-year follow-up study on the use of a levonorgestrel intrauterine system in women receiving hor-mone replacement therapy. Fertil Steril 76 969-973.